BAFF Polypeptide Modulation of Gut-Derived B Cells for MS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating autoimmune diseases, such as multiple sclerosis, are inadequate as they fail to effectively target and regulate B cells, leading to incomplete suppression of autoimmune responses and potential disease exacerbation.
Innovation Solution
Administering a B-cell Activating Factor (BAFF) polypeptide, either alone or in combination with agents that promote the survival and migration of gut-derived commensal-reactive B cells to the central nervous system, or deplete B cells, to modulate autoimmune responses and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD20 antibodies are used to deplete B cells, then autoimmune responses are suppressed, but CD20 negative pathogenic B cells are not targeted
Solution Approach 1:
The patent changes the target parameter from CD20 surface marker to BAFF receptor expression, enabling identification and targeting of a different B cell population (CD20 negative pathogenic B cells) that was previously inaccessible to standard therapies
Solution Approach 2:
The patent uses BAFF as an intermediary molecule to selectively enrich commensal-reactive B cells, which then serve as a bridge to modulate the broader immune response and protect against autoimmune damage
2Object-affected harmful factors
If B cells are depleted to treat autoimmune disease, then inflammatory lesions are prevented, but protective immune responses are also reduced
Solution Approach 1:
The patent applies local quality by selectively targeting and depleting only the pathogenic B cell subset (CD20 negative, non-commensal reactive) while preserving the protective commensal-reactive B cells through BAFF-mediated enrichment
Solution Approach 2:
Instead of depleting all B cells as in conventional therapy, the patent inverts the approach by selectively enriching and protecting the beneficial commensal-reactive B cell population, which then indirectly suppresses pathogenic responses
Data Source
Figure 1A
Figure 1B~1D
Figure 1E~1F
AI summary
The present disclosure provides methods of treating an autoimmune disease (e.g., multiple sclerosis) by administering at least a B-cell activating factor (BAFF) polypeptide to a subject in need thereof. A method of treating an autoimmune disease by administering BAFF in combination with gut derived IgA+ plasmablasts and/or plasma cells; or a gut commensal that increases IgA levels in the subject is also disclosed.